Common Challenges in Oncology Trials and What We Actually Do About Them

There’s a version of oncology clinical trials that looks clean on paper, with clear eligibility criteria, defined endpoints, carefully modeled dose-escalation plans, and safety stopping rules that feel reassuringly structured. And then there’s the version we actually live in.

In reality, patients don’t read protocols, biology doesn’t follow cohorts, and toxicity rarely shows up in neat, textbook patterns. The longer you work in early-phase oncology, the more you realize that the real work isn’t executing a plan; it’s constantly recalibrating in response to what’s unfolding in front of you.

Some challenges come up so often they almost feel predictable, but how we respond to them determines whether trials stay on track or quietly start drifting.

The protocol looks precise, but the patients are not.

One of the earliest challenges in any oncology study is determining eligibility. On paper, it seems straightforward: participants either meet the criteria or they don’t. But, in reality, this process is rarely as simple as it appears. 

You get patients who technically meet the criteria, but only just. Their organ function is borderline. A previous therapy doesn’t quite fit the exclusion criteria. They have residual toxicities that are labeled as “Grade 1,” but they feel more severe than that suggests. This is where trials begin to deviate from the norm.

Sites are eager to enroll, sponsors want momentum, and there’s an unspoken pressure to interpret the protocol in a way that allows patients to participate in the trial. The challenge isn’t just determining eligibility but also maintaining consistency. Once a borderline decision is made, it becomes a precedent, and your study population may no longer align with your initial expectations.

What actually works here isn’t stricter criteria; it’s clearer thinking. You need a shared understanding across the study of what “appropriate enrollment” really means. Not just what’s allowed, but what aligns with the scientific and safety goals of the trial.

The best studies I’ve seen aren’t the ones with the most stringent protocols. Instead, they’re the ones where eligibility decisions are openly discussed, challenged, and aligned early on, before patterns form.

Toxicity doesn’t read like CTCAE tables

If you’ve ever reviewed adverse events in an oncology trial, you already know the grading system. It’s a useful and necessary tool, but it doesn’t capture the full story. For example, a Grade 2 event in one patient is not the same as a Grade 2 in another. And more importantly, early low-grade signals often carry more weight than they appear to.

As you delve deeper, you begin to notice patterns. A slightly higher-than-expected rate of fatigue, mild transaminase elevations that don’t resolve quickly, and subtle immune-related symptoms that don’t quite meet criteria but feel like they’re building toward something. 

The challenge here is timing. If you wait for events to become “significant” by formal definitions, you’re already behind.

This is where medical monitoring becomes less about categorization and more about interpretation. You’re not just asking, “What grade is this?” You’re asking, “What does this mean in the context of this mechanism, this population, and this combination?”

The reality is, most safety signals don’t present themselves clearly. They emerge gradually, and whether you catch them early or late changes everything, from dose decisions to patient outcomes.

Combination therapy is where complexity multiplies

Monotherapy trials are already challenging enough, but most oncology development today involves combining drugs. This approach introduces a different kind of uncertainty.

When toxicity appears, it becomes difficult to determine its attribution. Is it the investigational drug? The backbone therapy? An interaction between the two? Something patient-specific? The protocol may provide some guidance, but in practice, you often have to make real-time judgment calls. 

What complicates things further is that combinations can create entirely new toxicity profiles that weren’t predictable from either drug alone. I’ve seen trials where each individual drug had a manageable safety profile, but when combined, they produced overlapping or amplified effects that changed how patients tolerated therapy altogether.

The challenge isn’t just managing toxicity; it’s understanding it. This requires more than individual case reviews; it requires pattern recognition across patients, cohorts, and sometimes even studies. By connecting the dots, you can make the most meaningful adjustments. 

Data comes in late and decisions don’t wait

In an ideal world, every decision would be made based on complete, clean, and up-to-date data. But this is not the reality of trials.

Data entry delays, open queries, and source verification lagging behind real-time events create a challenging environment. Decisions about dose escalation, cohort expansion, and safety signals still need to be made, often with limited visibility. This situation is particularly uncomfortable, especially in the early stages of development when small datasets carry significant weight.

The challenge here isn’t just in data quality but also in making decisions under uncertainty. It’s crucial to know when to take action and when to pause and wait. While some teams prioritize speed, others emphasize caution. However, neither approach is effective if it’s inconsistent.

Transparency is the key to avoiding mistakes.  It involves clearly communicating your knowledge, limitations, and how those uncertainties impact your recommendations.  Pretending the data is more complete than it is, is where mistakes happen.

Enrollment pressure quietly reshapes studies

No one talks about this as openly as they should. Enrollment is always a pressure point, and timelines and milestones matter. When accrual slows, the instinct is to find ways to fix it. 

Consider broadening the criteria, opening more sites, revisiting exclusions, and pushing borderline cases through. While these individual decisions may seem reasonable, collectively, they can significantly change the study.

As a result, you end up with a population that’s more heterogeneous than planned. This leads to different baseline risks, varying tolerability, and distinct response dynamics. And interpreting both efficacy and safety becomes more complex.

The challenge isn’t in enrollment itself but in maintaining the integrity of the study while trying to move it forward. Achieving that balance is harder than it sounds because the right decision for enrollment isn’t always the right decision for the data.

Therefore, instead of relying on more checklists or rigid rules, we must find alternative approaches to address these issues.

What consistently works is alignment, early and ongoing.

Alignment on how eligibility is interpreted, on what constitutes a meaningful safety signal, on how conservative or aggressive the team wants to be with dose decisions, and on how uncertainty is handled.

The most effective trial teams I’ve worked with don’t wait for problems to force these conversations. They have them upfront and they revisit them as the study evolves. There’s also a shift that needs to happen in how we think about medical monitoring. It’ should be proactive, not reactive. 

If the role is limited to reviewing events after they’ve been entered and graded, you’re always behind the trial. The value comes from being slightly ahead of it—seeing patterns as they form, asking uncomfortable questions early, and being willing to slow things down when needed. This should be done subtly, not dramatically or disruptively, but enough to maintain the study’s integrity.

The part we don’t say out loud

Oncology trials are complex because the disease is complex, but that’s only part of it. They’re also complex because they sit at the intersection of science, urgency, and uncertainty, creating a delicate balance. Patients need options, sponsors need progress, teams need clarity, and those forces don’t always align neatly, making everyone’s jobs a little more challenging. 

The job, whether you’re a medical monitor, investigator, or sponsor, isn’t to eliminate that tension. It’s to navigate it without losing sight of why the trial exists in the first place. Because at the center of all of this isn’t the protocol, it’s the patient. 

The decisions we make, early, often, and sometimes with incomplete information, shape not just the study, but the experience of every patient who participates in it. While this aspect may not align neatly with guidelines, it holds the utmost importance.